Obstructive Clinical Trials

1 recruiting

Obstructive Trials at a Glance

578 actively recruiting trials for obstructive are listed on ClinicalTrialsFinder across 6 cities in 68 countries. The largest study group is Not Applicable with 230 trials, with the heaviest enrollment activity in Beijing, Philadelphia, and Miami. Lead sponsors running obstructive studies include AstraZeneca, China-Japan Friendship Hospital, and VA Office of Research and Development.

Browse obstructive trials by phase

Treatments under study

About Obstructive Clinical Trials

Looking for clinical trials for Obstructive? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Obstructive trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Obstructive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 578 trials

Recruiting

Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

Pediatric Obstructive Sleep Apnea
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)120 enrolled1 locationNCT05052216
Recruiting
Not Applicable

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

Chronic Obstructive Pulmonary DiseaseCOPD
Nuvaira, Inc.200 enrolled10 locationsNCT07051707
Recruiting
Phase 1Phase 2

Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia

Hypoxia, BrainBlood PressureStroke+5 more
University of Calgary12 enrolled1 locationNCT03255408
Recruiting
Not Applicable

Clinical Trial of the Cryosa System for the Treatment of Obstructive Sleep Apnea

Obstructive Sleep Apnea of Adult
Cryosa, Inc.25 enrolled9 locationsNCT06008626
Recruiting
Not Applicable

Measurement of Viscoelastic Properties of Bronchopulmonary Secretions.

Obstructive Pulmonary Disease
Cliniques universitaires Saint-Luc- Université Catholique de Louvain500 enrolled1 locationNCT03888300
Recruiting
Phase 2

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.165 enrolled56 locationsNCT07023614
Recruiting
Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep Apnea
Amgen250 enrolled38 locationsNCT07226765
Recruiting
Not Applicable

Post Market Clinical Follow up of ResMed Mask Systems

Obstructive Sleep Apnea
ResMed500 enrolled1 locationNCT05262439
Recruiting

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb362 enrolled1 locationNCT07557498
Recruiting
Phase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

ObesityObstructive Sleep Apnea
Amgen250 enrolled47 locationsNCT07225686
Recruiting

OSA as a Remote Ischemic Preconditioning in Vascular Surgery

Obstructive Sleep ApneaIschemia Reperfusion InjuryVascular Aneurysm
St. Anne's University Hospital Brno, Czech Republic100 enrolled1 locationNCT04630535
Recruiting
Phase 4

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease
Sanofi218 enrolled58 locationsNCT07053423
Recruiting
Not Applicable

Oropharyngeal Exercises to Treat Obstructive Sleep Apnea

Obstructive Sleep Apnea
Sunnybrook Health Sciences Centre45 enrolled1 locationNCT05678088
Recruiting

Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

Chronic Obstructive Pulmonary Disease
AstraZeneca1,400 enrolled21 locationsNCT07069829
Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Pulmonary Disease, Chronic Obstructive
AstraZeneca2,000 enrolled7 locationsNCT06712563
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled166 locationsNCT07190209
Recruiting

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Chronic Obstructive Pulmonary Disease
AstraZeneca1,000 enrolled20 locationsNCT06862206
Recruiting
Phase 3

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled188 locationsNCT07190222
Recruiting

Study of Patient With Frequent Exacerbations in Moscow

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca500 enrolled1 locationNCT07307781
Recruiting
Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled123 locationsNCT07369011